Globus Medical, Inc. (GMED) Stock: Price, Forecast & Analyst Target
Globus Medical, Inc. (GMED) — MoonshotScore 94/100 (Exceptional band), calculated Nov 18, 2026. Price $70.53 (+0.77%), as of the Nov 18, 2026 trading session; market cap $9.34B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 18.05× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Globus Medical, Inc. · GMED · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Globus Medical supplies implants and related technologies across spine surgery, orthopedic trauma, joint reconstruction, pain treatment, and regenerative biologics. Spine still supplies nearly all segment revenue, so recent profit and cash gains matter most if they persist while Emerging Technology becomes more consequential.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Globus Medical (GMED)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry. Business Quality: Elite; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $769M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 9.39 · Piotroski F 8
Helping: business quality, balance-sheet strength, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $70.53 | |
| Change on the day | +0.77% | |
| 52-week range | $69.49–$101.40 | |
| Market capitalisation | $9.34B | — |
| Price / earnings (trailing) | 16.91 | |
| Shares traded on the day | 1.43M | |
| Beta (volatility vs the S&P 500) | 0.96 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Globus Medical (GMED): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Globus Medical (GMED), and what does it report?
Short answer · as of
Globus Medical is not merely a maker of conventional spine hardware. Its portfolio reaches from fusion implants, disc replacement, and pain treatments to biologics, fracture fixation, and hip and knee reconstruction; demand therefore follows the use of these products in musculoskeletal procedures.
Research dated 2026-09-13.
The reporting shape remains much narrower than the catalogue suggests. Spine dominates disclosed segment revenue, while Emerging Technology contributes a comparatively small share, making the company financially spine-led despite its broader product reach.
What do the latest results show for Globus Medical (GMED)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $769M.
Research dated 2026-09-13.
The latest results extended a broad operating improvement: revenue advanced from the preceding period, gross profit rose, selling and administrative expense declined, and operating income, net income, and diluted earnings all increased. Revenue and earnings also exceeded market estimates, continuing a recent run of favorable surprises.
The accounting mechanism was stronger gross profit paired with tighter selling and administrative spending, while research and development expense remained broadly steady. The longer annual series reinforces the direction, showing revenue expansion accompanied by a sharp recovery in net income.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $763.72M Sep 30, 2026
- Latest quarter · R&D
- $34.53M Sep 30, 2026
- Latest quarter · SG&A
- $288.47M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $177.55M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $763.72M | $34.53M | $288.47M | $177.55M |
| Jun 30, 2026 | $789.61M | $36.32M | $286.82M | $182.43M |
| Mar 31, 2026 | $759.85M | $36.51M | $297.77M | $163.57M |
| Dec 31, 2025 | $826.39M | $73.92M | $456.28M | $171.68M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $763.72M Nov 5, 2026
- Latest report · revenue estimate
- $792.39M Nov 5, 2026
- Latest report · revenue vs estimate
- Below estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $763.72M | $792.39M | $1.2300 | $1.2000 |
| Aug 6, 2026 | $789.61M | $782.88M | $1.3400 | $1.1000 |
| May 7, 2026 | $759.85M | $740.35M | $1.1200 | $0.9200 |
| Feb 24, 2026 | $826.42M | $801.65M | $1.2800 | $1.0600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $769M | $119M | $0.88 (diluted) |
| Q4 FY2025 | $826M | $141M | $1.01 (diluted) |
| Q1 FY2026 | $760M | $124M | $0.90 (diluted) |
| Q2 FY2026 | $790M | $152M | $1.10 (diluted) |
What are the financial strengths and risks for Globus Medical (GMED)?
Short answer · as of
Cash and short-term investments were $517.43M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $265.23M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Globus Medical combines positive operating cash flow throughout the displayed reporting window with a cash and short-term investment balance that substantially exceeds total debt. Strong liquidity ratios, low financial leverage, and favorable distress and quality screens leave the business with meaningful financial flexibility after capital spending.
Cash has not accumulated in a straight line: the balance declined across the full displayed window and moved lower from the preceding period despite healthy operating cash generation. The operating risk is concentration rather than leverage; weakness in spine procedures or product uptake would strike the revenue base before the much smaller Emerging Technology segment could provide much insulation.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $265.23M Sep 30, 2026
- Previous quarter · operating cash flow
- $209.74M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $265.23M | −$40.39M |
| Jun 30, 2026 | $209.74M | −$33.17M |
| Mar 31, 2026 | $202.36M | −$39.61M |
| Dec 31, 2025 | $248.59M | −$56.20M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Globus Medical (GMED)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13.
Watch whether revenue holds near its recent high while gross profit continues to outpace operating expenses. Sustained operating cash generation after capital spending would show that the earnings improvement is converting into financial capacity rather than merely appearing on the income statement.
Market estimates anticipate continued expansion in revenue and earnings over the coming years. The useful confirmation would be repeated progress in reported earnings, cash conversion, and Emerging Technology relevance; renewed expense pressure or fading revenue momentum would weaken that pattern.
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Globus Medical compare with its peers?
Short answer
Globus Medical's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Globus Medical differs from a narrowly focused implant maker because its catalogue spans traditional fixation, motion preservation, pain intervention, biologics, trauma hardware, and joint reconstruction. Yet its disclosed economics remain dominated by Spine, so portfolio breadth should not be mistaken for balanced segment diversification.
The combination of high gross margins, low debt, positive cash generation, and continued research spending gives Globus Medical room to support that breadth. Emerging Technology is the clearest route to a more differentiated revenue mix, but its current scale leaves spine demand as the dominant commercial exposure.
| Company | Price | Market value | Score |
|---|---|---|---|
| Globus Medical (GMED) — this page | $70.53 | $9.34B | 94 |
| $320.50 Nov 18, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $161.75 Nov 18, 2026 | $10.2B | 76 5-pillar Nov 18, 2026 | |
| $85.69 Nov 18, 2026 | $9.47B | 73 5-pillar Nov 18, 2026 | |
| $206.56 Nov 18, 2026 | $10.8B | 68 5-pillar Nov 18, 2026 | |
| $126.97 Nov 18, 2026 | $4.32B | 68 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $78.00 – $100.00
- Consensus target
- $87.50
- Median target
- $83.50
Consensus record · Captured .
Measured against a quoted price of $70.53 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 23
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 6
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 88.2% Period end Sep 30, 2026
- Previous quarter · ownership
- 88.8% Prior to period end Sep 30, 2026
- Reporting holders
- 626 Period end Sep 30, 2026
- Previous quarter · holders
- 618 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 10,906,047 |
| Janus Henderson Group Ltd. | 8,634,195 |
| Vanguard Capital Management LLC | 5,075,559 |
| Vanguard Portfolio Management LLC | 4,866,366 |
| State Street Corp | 3,718,553 |
Tracked investors
Which of the 16 named investors we follow held GMED in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.10% | $23.72M | Trimmed −10.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Globus Medical (GMED)?
Globus Medical Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Globus Medical more than a spine implant company?
Its portfolio also includes trauma fixation, hip and knee reconstruction, pain treatments, regenerative biologics, and motion-preservation products. Financially, however, disclosed segment revenue remains overwhelmingly tied to Spine.
Can Emerging Technology diversify Globus Medical away from Spine?
Emerging Technology provides a distinct growth avenue, but its disclosed revenue contribution remains small beside Spine. Meaningful diversification requires that gap to narrow over time.
Are Globus Medical’s earnings gains producing operating cash?
Operating cash flow has remained positive throughout the displayed reporting window, including during the recent improvement in operating and net income. Recurring capital expenditure absorbs part of that cash, while the cash balance itself has fluctuated materially.
Has Globus Medical’s spine-led portfolio kept beating market expectations?
Recent reports have delivered revenue and earnings above market estimates after an earlier miss. Maintaining that pattern depends on revenue momentum and continued conversion of gross profit into operating earnings.
What is the GMED stock price today?
The last price recorded for Globus Medical, Inc. (GMED), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GMED price target?
The analyst consensus price target for Globus Medical, Inc. (GMED), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 1 from SEC filings and earnings calls, 75 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com